牛牛AI助理已提取核心訊息
David Young, Processa Pharmaceuticals' President of Research & Development, completed a purchase of 21,000 shares of common stock on February 7, 2024. The transaction was carried out on the open market at a price of $2.4536 per share. Following this acquisition, Young's direct holdings in the company increased to 79,387 shares. Additionally, Young has indirect ownership of 60,315 shares through various entities, including the Young-Plaisance Revocable Trust, Family Entities, and CorLyst, LLC. The total value of the shares acquired in the transaction is approximately $51,525.60.
David Young, Processa Pharmaceuticals' President of Research & Development, completed a purchase of 21,000 shares of common stock on February 7, 2024. The transaction was carried out on the open market at a price of $2.4536 per share. Following this acquisition, Young's direct holdings in the company increased to 79,387 shares. Additionally, Young has indirect ownership of 60,315 shares through various entities, including the Young-Plaisance Revocable Trust, Family Entities, and CorLyst, LLC. The total value of the shares acquired in the transaction is approximately $51,525.60.
Processa Pharmaceuticals研發總裁大衛·楊於2024年2月7日完成了對21,000股普通股的購買。該交易在公開市場上進行，價格爲每股2.4536美元。此次收購後，楊在公司的直接持股量增加到79,387股。此外，楊通過各種實體間接擁有60,315股股份，包括Young-Plaisance可撤銷信託、家族實體和CorlyST, LLC。交易中收購的股票的總價值約爲51,525.60美元。
Processa Pharmaceuticals研發總裁大衛·楊於2024年2月7日完成了對21,000股普通股的購買。該交易在公開市場上進行，價格爲每股2.4536美元。此次收購後，楊在公司的直接持股量增加到79,387股。此外，楊通過各種實體間接擁有60,315股股份，包括Young-Plaisance可撤銷信託、家族實體和CorlyST, LLC。交易中收購的股票的總價值約爲51,525.60美元。
有用
沒用